News Sentiment

CMPX sentiment intelligence

Compass Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.33 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.6% over one week, +14.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 2.6% Price confirming higher
Trend fit Trend inactive 14.8% over four weeks
Fair value -11.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 34
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 9
TradingKey 6
Insider Monkey 5
GlobeNewswire 4
Stock Titan 3
The National Law Review 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 19
Analyst action 6
Regulatory and legal 3
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
TradingView Direct company coverage

CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead

Compass Therapeutics (CMPX) is advancing four oncology assets, with its lead drug, tovecimig, showing strong efficacy in BTC and nearing FDA submission. The company anticipates multiple clinical and regulatory catalysts within the next year and has a cash runway extending into 20

Tone
Positive 72/100
Event
Earnings
Published
09 Jun 2026 13:09
Source
TradingView
Barchart Direct company coverage

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics is preparing for an FDA meeting in early August regarding its drug tovecimig, a DLL4/VEGF bispecific antibody, after successful trial results in advanced biliary tract cancer. The COMPANION-002 study met its primary endpoint of overall response rate and signi

Tone
Positive 73/100
Event
Earnings
Published
09 Jun 2026 03:10
Source
Barchart
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)

This article highlights bullish sentiments from three analysts regarding several healthcare companies. Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines (PRAX) with a $1245.00 price target. Biren Amin from Piper Sandler maintained a Buy ratin

Tone
Positive 76/100
Event
Analyst action
Published
02 Jun 2026 13:39
Source
The Globe and Mail